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Summary 
Conclusion. Based on these data we suggest hat regional intra-arterial chemotherapy for advanced pancre- 
atic cancer seems not to be superior to common treatment modalities, such as combined radiochemotherapy. 
Background. The prognosis for advanced pancreatic cancer is very poor. No standard treatment is
available. Recently, better survival and quality of life was reported from regional cancer treatment via celiac 
axis infusion. In an attempt to confirm these results we conducted a phase II study of intra-arterial chemo- 
therapy for nonresectable pancreatic cancer. 
Methods. From May 1994 to February 1995, 12 consecutive patients with biopsy-proven advanced ductal 
carcinoma of the exocrine pancreas were given intra-arterial infusions consisting of Mitoxantrone, 5-FU + 
folinic acid, and Cisplatin via a transfemorally placed catheter in the celiac axis. Six patients were classified 
as UICC stage III and six as stage IV with the liver as the sole site of distant metastasis. Nine patients had 
primary and three had recurrent pancreatic carcinoma fter a Whipple procedure. Nonresectability of
primary tumors was assessed in all patients by laparotomy or laparoscopy. 
Results. A total of 31 cycles of chemotherapy (mean 2.6 cycles/patient) was administered. Catheter place- 
ment was technically feasible in all cycles. A groin hematoma was the only catheter complication. The 
follow-up by CT scans at 2-mo intervals revealed partial remission in 1 patient (8o70), temporary stable 
disease in 4 patients (33o70), and disease progression i 7 patients (58o7o). The same response was obtained 
after analyzing the CA 19-9 course. Median survival in stage III patients was 8.5 mo (3-12 mo) and in stage 
IV patients 5mo (2-11 mo). Toxicity according to WHO criteria consisted of grade III (4 events), grade II 
(10 events), and grade I (17 events), mainly resulting from leucopenia nd diarrhea/vomiting. Nine of 11 
patients experienced temporary relief of pain immediately after regional treatment. 
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Introduction 
Pancreatic ancer is the fourth leading cause of 
death from cancer in the Western world (1), and the 
incidence of this disease continues to increase. 
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Despite improved diagnostic facilities and surgical 
techniques, the prognosis of pancreatic ancer has 
not improved much over the last decades (2,3). 
Resection rates range from 5 to 42~ (4), but in two 
recent meta-analyses the resectability rates were 
only 11 and 12%, respectively (5,6). Of the many 
surgical and medical palliative treatment options, 
the best result was obtained by radiotherapy in com- 
bination with systemic chemotherapy, increasing 
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median survival in loco-regional advanced, nonre- 
sectable pancreatic cancer to 10-12 mo (7-9). How- 
ever, this median survival time is still modest and no 
standard treatment is available for advanced pan- 
creatic cancer (10). In an attempt to overcome this 
desperate situation, HafstriAm and coworkers chose 
in as early as 1974 the celiac axis as the route for drug 
administration (11) in order to increase the drug 
concentration in the pancreatic tumor and the drain- 
ing lymphatics (12). However, it was not until 1990, 
when the technique of arterial catheter infusion had 
improved and new cytotoxic drugs were available, 
that improved survival was reported from studies 
with intra-arterial chemotherapy for nonresectable 
pancreatic arcinoma (13-17). Aigner et al. (14) 
treated 26 patients with nonresectable pancreatic 
cancer with intra-arterial infusion of Mitomycin C, 
Cisplatin, and 5-Fluorouracil via the celiac axis. 
Twenty-one patients had liver metastases and 4 had 
carcinomatosis of the peritoneum. The response 
rate, indicated by tumor markers, was 77~ The 
median survival time was 10.2 mo for patients with 
no previous resection and 6 mo for patients with 
recurrence after a Whipple procedure. At repeated 
laparotomy after four courses of intra-arterial infu- 
sion therapy, 4 out of 10 tumors turned out to be 
locally resectable. In another German institution, 
intra-arterial dministration f Mitoxantron, 5-FU 
plus Leucovorine, and Cisplatin led to a median 
survival of 12 mo in 17 patients with nonresectable 
pancreatic cancer of UICC stage III and of 4 mo in 
15 patients with UICC stage IV disease (13). Toxici- 
ties of WHO grades III and IV were encountered in 
< 10o70 of the patients and pain decreased signif- 
icantly with the initiation of regional chemotherapy. 
The aim of the present prospective and controlled 
study was to conf'Lrm these promising data. 
Patients and Methods 
Patients 
Between May 1994, and February 1995, 33 conse- 
cutive patients suffering from pancreatic ancer 
were referred to our surgical department. Fifteen 
tumors were surgically removed, 6patients with non- 
resectable tumors refused regional chemotherapy, 
and 12 patients (9 males, 3 females, mean age 59.9 
[43-77] yr) with nonresectable pancreatic carcinoma 
were treated by regional chemotherapy through 
celiac axis infusion. Of the latter, 9 patients had 
primary and 3 patients had recurrent pancreatic 
cancer. The tumor sites were the pancreatic head 
(7 patients), the body (1), the body and tail (1), and 
the region of former pancreatic resection (3). In 
primary tumors, nonresectability was assessed in 8 
patients by laparotomy and in one patient by laparo- 
scopy. A palliative bypass procedure was performed 
in four cases and four laparotomies remained explor- 
ative. All 12 patients had biopsy-proven ductal ade- 
nocarcinoma of the pancreas. The tumors were 
graded as moderately (10 cases) to poorly (2 cases) 
differentiated. Six patients were classified as UICC 
stage III (Tx N1 M0) and 6 as stage IV (Tx Nx M1). 
All patients of the latter group had liver metastases 
as the sole site of distant disease. These patients 
were included since therapeutic drug levels in the 
liver are obtained by intra-arterial infusion via the 
celiac axis. No peritoneal carcinomatosis was encoun- 
tered at the time of laparotomy and laparoscopy, 
respectively. No patient had previous systemic 
chemotherapy, immunotherapy, or irradiation. 
The study was approved by the Ethics Committee 
of the University of Bern, Switzerland. Written 
informed consent was obtained from each patient. 
Regional Intra-Arterial Treatment 
In order to reach high local drug levels in the 
pancreas, the peripancreatic lymphatic network, and 
the liver, drugs were infused into the celiac axis, using 
a transfemoraUy placed, temporary catheter. This 
catheter was left in place for five consecutive days 
for each cycle. The catheter position was checked 
on d 1, 2, and 5 by angiography and patients had to 
stay in bed for this 5-d period to prevent catheter 
dislocation. Prophylactic infusion of 20,000 IU of 
heparin was administered continuously via the 
arterial catheter to avoid thrombosis. 
Chemotherapeutic drugs were given as daily infu- 
sions consisting of Mitoxantrone 10 mg/m 2 (for 60 
min, d 1) and folinic acid 170 mg/m 2 (for 10 min), 
followed by 5-FU 600 mg/m 2 (for 120 min, d 2-4) 
and Cisplatin 60 mg/m 2(for 60 min, d 5). The cycles 
were repeated at 6-wk intervals (range 4-9 wk) up to 
disease progression. Supportive measures consisted 
of the administration f proton pump blockers and 
selective serotonin receptor-3 antagonists. One 
patient received systemic 5-FU therapy after docu- 
mented tumor progression. One patient underwent 
a second-look laparotomy after two cycles of intra- 
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arterial chemotherapy but turned out not to be 
resectable. 
Follow-Up 
In order to monitor the response, CT scans or 
magnetic resonance imaging (MRI) of the abdomen 
and X-rays of the lung were performed at the begin- 
ning of the treatment and after every two cycles. 
The plasma levels of CA 19-9 and CEA were ana- 
lyzed at the start of each cycle. Response valuation 
of measurable disease and of serum tumor markers 
as well as the determination f toxicity were per- 
formed according to WHO criteria (18). White 
blood cell (WBC) and platelet counts were assessed 
at weekly intervals. 
Results 
Response 
Twelve patients received a total of 41 cycles of 
intra-arterial chemotherapy (mean 2.6 cycles/patient, 
range 1-5 cycles). Two patients had only one cycle 
of chemotherapy: One with UICC stage III disease 
refused any further treatment and one with stage IV 
disease had rapid deterioration. As assessed by CT 
scans, one partial remission (8~ four cases of 
temporary stable disease (33~ and seven of disease 
progression (58O7o) were observed. A parallel 
response pattern was obtained by the analysis of the 
course of the tumor marker CA 19-9: one patient 
with partial remission, four with no change, and 
seven with progressive disease. Pain was a major 
problem in 11 of 12 patients before the start of 
chemotherapy. With regional cancer treatment the 
pain was reduced completely inone patient and to a 
substantial extent in eight patients. In two cases no 
beneficial effect on pain was observed. Despite 
therapy, the mean monthly weight loss was 2.7 kg. 
Only 2 of 12 patients could maintain their weight 
during the course of treatment. 
The median survival in the whole group was 6 mo 
(range 2-12 mo). UICC stage III patients urvived 
for a median of 8.5 mo (range 3-12 mo) and UICC 
IV patients for a median of 5 mo (2-11 mo). 
Side Effects and Complications 
Catheter placements were technically possible in 
all 31 cycles. No intimal damage occured. The only 
complication of arterial puncture and catheter 
Tab le  1 
Events  o f  Systemic Tox ic i ty  in 31 Cycles o f  Cel iac  Axis  
Drug  In fus ion ,  Accord ing  to WHO Cr i ter ia  
Toxicity 
(n = 31 cycles) WHO I WHO II WHO III WHO IV 
Leucopenia 6 4 2 - -  
Vomiting/diarrhea 6 6 1 - -  
Renal 5 - -  - -  - -  
Fever/ infection - -  - -  1 - -  
Cutaneous/hair  . . . .  
Neurotoxicity . . . .  
placement was one groin hematoma after catheter 
removal, which was treated conservatively. 
Drug-induced loco-regionai toxicity consisted of 
upper abdominal pain in three cycles. Gastroduod- 
enoscopy revealed one instance of duodenal ulcer 
without the need for surgical intervention. Drug- 
induced systemic toxicity is listed in Table 1. No 
grade IV toxicity was encountered. However, there 
were four events of grade III toxicity and ten of 
grade II, all but one of them resulting from leuco- 
penia and vomiting/diarrhea. One patient devel- 
oped a suppurative peritonitis with gram-negative 
sepsis. In all, 33 toxic events were recorded in 31 
cycles (1.06 events/cycle). Dose reduction was made 
only in one case because of leucopenia. No pulmo- 
nary or cardiac side effects were observed. 
Discussion 
Regional intra-arterial chemotherapy via celiac 
axis infusion has been advocated in an attempt to 
improve the dismal prognosis of nonresectable pan- 
creatic ancer (13-17). The results obtained in these 
studies inspired us to treat 12 consecutive patients 
suffering from nonresectable pancreatic carcinoma 
via celiac axis infusion. The same drug schedule was 
used as in one report (13). However, the results of 
this study were disappointing, sowe felt compelled 
to end the study sooner than planned. In this study, 
the median survival of 8.5 mo in UICC stage III 
disease and 5 mo in stage IV pancreatic cancer was 
inferior when compared with the results of the 
abovementioned studies (13,14,16,17). In addition, 
they did not seem superior to historical data with 
systemic chemotherapy combined with radiotherapy 
(9). The median survival time of 6 mo for all patients 
in this study is well in accordance with the reported 
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survival of 6.5 mo in an earlier study (11). In that 
article 10 and 9 patients with stage III and IV pan- 
creatic carcinoma were treated with intra-arterial 
5-FU infusion with or without oral testolactone. 
Furthermore, we observed a considerable amount 
of toxic side effects, including grade III toxicity 
(according to WHO criteria) in one-third of our 
patients. The following discussion might give some 
explanations for our disappointing experience with 
celiac axis drug infusion for nonresectable pan- 
creatic ancer: 
1. In the present study only patients with ductal 
adenocarcinoma of the pancreas were included, 
whereas other pancreatic tumors (cystadenocar- 
cinoma, mucinous carcinoma, naplastic cancer) 
with different prognoses made up 12.5070 of 
other authors tudies (13). 
2. All of our patients had very advanced tumor 
stage, since resectability of the primary pancrea- 
tic tumor had been explored in all patients by 
laparotomy or laparoscopy. This is not the case 
in other studies (9,19). Since we follow an aggres- 
sive resection strategy in pancreatic cancer with 
a resectability rate of 51070 (130 referrals in the 
last 3 yr) the nonresectable patients actually rep- 
resent aselection of patients with very advanced 
disease. 
3. Three of our patients were treated because of 
loco-regional recurrence that seems to be associ- 
ated with an even poorer prognosis and resis- 
tance to regional cancer treatment, respectively 
(14,20). 
4. Eight of 9 primary pancreatic ancers in this 
series were explored by laparotomy. The resul- 
tant immunotrauma might have compromised 
the survival. 
5. The patients in the present study were checked 
by CT scan at 2-mo intervals. This close follow- 
up might have detected tumor progression earlier 
than in the other studies (13,14). Therefore, the 
regional cancer treatment might also have been 
stopped earlier in some of our patients. 
6. The mean interval between the cycles of therapy 
is longer in this study than in the previous 
reports. This is mainly because of the increased 
toxicity in our group of patients. 
7. We did not use actuarial survival to calculate the 
median survival times. 
8. A lack of experience with regional cancer treat- 
ment can be ruled out as cause for our unsatis- 
fying results ince a specialized team of nurses, 
oncologists, urgeons, and radiologists i  respon- 
sible for the care of patients undergoing regional 
chemotherapy (21-23). This experience is also 
reflected in the low complication rate of catheter 
placement. 
Taken together, guaranteed nonresectability, close 
follow-up, and meticulous recording of side effects 
led to rather disappointing results of the regional 
treatment approach for advanced pancreatic cancer. 
A considerable disadvantage of the regional treat- 
ment approach is the need for patient admission to 
the hospital for at least 5 d per cycle at the occasion 
of drug administration. The hospital stay is an addi- 
tional stress for a patient with a short life expectancy. 
Furthermore, using our drug schedule the percuta- 
neous transfemoral catheter placement implies a 5-d 
period of inconvenient bed rest. The costs of this 
palliative treatment are considerable. Some authors 
report their attempt o overcome the problem of 
immobilization by the implantation of celiac axis 
port catheters via laparotomy. However, surgical 
exposure of the celiac trunk can be a very challeng- 
ing and risky enterprise in advanced pancreatic 
cancer. Furthermore, the tip of the catheter in the 
celiac axis blood stream causes local turbulence and 
therefore favors arterial thrombosis (23). Increased 
ulcer formation might also be the consequence of 
infusion chemotherapy viaceliac axis ports and prob- 
ably the cause of consecutive arterial thrombosis (13). 
Although we are convinced of the beneficial 
effect of the arterial treatment approach for isolated 
primary and secondary liver tumors, we believe that 
a different rationale applies to the regional treat- 
ment of pancreatic cancer because of the complex 
vascular anatomy. The pancreas has mainly a dual 
blood supply via the celiac axis and superior mes- 
enteric artery. However, it has not been shown that 
all pancreatic regions, especially the pancreatic head, 
are dependent on arterial blood from the celiac 
axis. Donatini found in 69 anatomical pancreatic 
dissections a lack of arterial anastomosis between 
these two main arteries in 33070 of cases (12). Addi- 
tionally, arterial stenoses resulting from the pan- 
creatic tumor might further compromise sufficient 
drug delivery to the target region. Figure 1 may 
illustrate such a situation in a patient with a large 
adenocarcinoma of the pancreatic body. In this 
case, catheter insertion into the celiac axis (place- 
ment in the splenic artery was not possible) mainly 
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Fig. 1. Celiacography in a patient suffering from 
adenocarcinoma of the pancreatic body: the tip of the 
transfemorally placed arterial catheter ispositioned in the 
celiac axis. (A) Celiac trunk, 011) common hepatic artery, 
(C) left gastric artery, and (D) splenic artery with rele- 
vant, long distance stenosis (arrows) caused by pancreatic 
tumor growth. Cytotoxic drugs may not reach the pan- 
creatic tumor sufficiently by celiac axis infusion. 
supplied the hepatic artery and left gastric artery but 
not the splenic artery with cytotoxic drugs. Hence, 
drug delivery to the tumor might have been insuffi- 
cient. The special topographic anatomy of the pan- 
creatic arterial system might therefore render the 
arterial approach unsuitable for the treatment of 
nonresectable pancreatic cancer. 
A positive ffect of regional chemotherapy in our 
study was a rapid and repeatable r duction of pain 
in 82o70 (9/11) of our patients. This fact is in accor- 
dance with other papers reporting significant pain 
reduction in 55~ (24) and "nearly all" patients 
(13), respectively. We hypothesize that the cytotoxic 
drugs used are also toxic to peripancreatic nerves 
that are often infiltrated or accompanied by the 
growing pancreatic arcinoma (25,26). However, 
the therapeutic goal of pain reduction ismore easily 
achieved by application of central analgesics, block- 
ade of the celiac nerve plexus by ethanol instillation, 
or thoracoscopic resection of splanchnic nerves. 
Conclusion 
Based on this prospective series we cannot 
recommend regional treatment of advanced pancre- 
atic cancer via celiac axis nfusion with t e drugs used 
for this study. Celiac axis infusion chemotherapy 
should not be given outside clinical trials examining 
novel drug combinations or comparing regional 
treatment to other treatment approaches. 
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